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Abstract
Background: Colorectal cancer is a one of the most common alimentary malignancies. Survivin
has been proved by many studies to be an ideal target for cancer gene therapy because of its strong
anti-apoptotic effect. The reduction of Survivin expression by means of chemically synthesized small
interfering RNA or small hairpin RNA expressed from plasmid and resulted growth inhibition of
cancer cells had been proved by many studies including ours, but the transfection efficiency was not
encouraging. So for the first time we constructed the Survivin shRNA into an oncolytic adenovirus,
tested its effects on colorectal cancer cell lines and nude mice xenograft model.
Methods: In this study, we constructed an oncolytic adenovirus with a Survivin targeted small
hairpin RNA and a reporter gene (ZD55-Sur-EGFP). The expression of Survivin mRNA and protein
were analyzed by RT-PCR and western blot. The cell growth and apoptosis were tested by in vitro
cytopathic assay, MTT assay and flow cytometry respectively. The effect of the constructed virus
on xenograft model was evaluated by tumor volume and western blot analysis.
Results: ZD55-Sur-EGFP replicated in cancer cells specifically, reduced the expression of Survivin
mRNA and protein expression effectively (P < 0.0001), induced cancer cell apoptosis and inhibited
SW480 cell growth both in vitro and in vivo significantly.
Conclusion:  We conclude Survivin RNA interference combining with oncolytic adenovirus
virotherapy to be a promising treatment for colorectal cancer.
Background
Colorectal cancer (CRC) is the second leading cause of
cancer-related deaths in the US and the incidence is
increasing rather rapidly in developing countries includ-
ing China [1]. Traditional treatments for colorectal cancer
such as surgical resection and chemotherapy do not
increase the survival rate satisfactory enough. There are
still 50% patients died from tumor recurrence and metas-
tasis. It is of great importance to find a new therapeutics
against colorectal cancer.
Survivin, a member of the inhibitor of apoptosis protein
(IAP) family, is expressed highly in most human tumors
and fetal tissues, but is barely detectable in terminally dif-
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ferentiated cells [2]. The Survivin protein functions to
inhibit caspase activation by interacting with caspases via
baculovirus IAP repeat domains, therefore leading to neg-
ative regulation of apoptosis [3]. There was evidence by
cDNA microarray that Survivin plays an important role in
pathogenesis of colorectal cancer [4]. Several reports had
successfully inhibited cancer cell growth by applying Sur-
vivin antagonists, antisense oligonuceotides or Survivin
RNA interferences [5-7]. Thus Survivin is considered as an
ideal target for colorectal cancer gene therapy [8].
ONYX-015, a well known E1B-55 kDa deleted adenovi-
rus, has been used in clinical trials and achieved encour-
aging results. However, the therapeutic efficacy of ONYX-
015 is limited when it is used as a single agent [9,10]. So
we constructed a new E1B-55 kDa deleted adenovirus
with a cloning site for exogenous gene, which offered a
possibility for treatment of carcinomas with both onco-
lytic adenovirus and specific gene targeted RNA interfer-
ence. We showed that the construct, ZD55-Sur-EGFP,
specifically replicated in colorectal cancer cells, induced
apoptosis and attenuated cancer cell growth both in vitro
and in nude mice. ZD55-Sur-EGFP may be a promising
therapy for colorectal cancer.
Methods
Construction of Survivin shRNA expression plasmid
A pair of short hairpin RNA (shRNA) targeting Survivin
[GeneBank accession NM_001168] which had been
reported [6] was constructed. The sequence was a 19 nt
small interfering RNA: GGCTGGCTTCATCCACTGC (86–
104) with a ring sequence of 9 base pairs connecting the
sense and antisense strands (TTCAAGAGA). The shRNA
was constructed into pMD-18T plasmid (TaKaRa),
namely pMD-18T-S. The sequence was not homologous
with any human coding gene by BLAST analysis.
Cell lines and cell culture
Human colon adenocacinoma cell lines SW480, LoVo
and intestinal epithelial cell (IEC) were obtained from
Shanghai Cell Collection (Shanghai, China), HEK293
cells were purchased from Mircrobix Biosystems Ltd.
(Canada). Cells were routinely cultured in Dulbecco's
modified Eagle's media (Gibco) supplemented with 10%
(vol/vol) fetal bovine serum (Gibco) at 37°C in a humid-
ified incubator containing 5% CO2.
Adenovirus construction
We constructed an E1b-55 kDa deleted oncolytic adenovi-
rus construction plasmid pZD55 as reported [11] and it
was reserved in our laboratory, but we added a reporter
gene expressing enhanced green fluorescence protein
(EGFP) which allowed for tittering and measuring of
infection efficiency in transfected cells. Briefly, pIRES-
EGFP (Clontech) was cut with EcoRI and XbaI to get the
EGFP fragment. Then the EGFP segment was ligated into
pCA13 (Microbix Biosystems) and pZD55 respectively to
form pCA13-EGFP and pZD55-EGFP. After that, the Sur-
vivin shRNA expression cassette was excised from pMD-
18T-Sur with XhoI and BamHI, first subcloned into
pCA13-EGFP to form pCA13-Sur-EGFP. Then the expres-
sion cassette containing the Survivin shRNA controlled by
the human CMV promoter and reporter gene EGFP were
cut with Bgl II and subcloned into pZD55 to construct
pZD55-Sur-EGFP. Oncolytic adenoviruses ZD55-Sur-
EGFP, ZD55-EGFP, replication deficiency adenovirus AD-
Sur-EGFP, AD-EGFP were generated by homologous
recombination between pZD55-Sur-EGFP, pZD55-EGFP,
pCA13-Sur-EGFP, pCA13-EGFP and the adenovirus pack-
aging plasmid pBHGE3 (Microbix Biosystems) respec-
tively. Viruses were purified by ultracentrifugation with
cesium chloride. The titers were determined by cytopathic
effect (CPE) on HEK293 cells in a 96-well plate by a fluo-
rescence microscope.
Detection of adenoviruses in cells
SW480 and LoVo cells as well as intestinal epithelial cells
(IEC) were plated at 105 cells per 6 cm dish and infected
with ZD55-Sur-EGFP or AD-Sur-EGFP for 48 h and 72 h.
The expression of enhanced green fluorescent protein
(EGFP) was accessed by a Zeiss fluorescence microscope
coupled with a digital camera photo apparatus.
RT-PCR analysis
Total RNA from transfected cells was isolated using TRIzol
(Invitrogen) as recommended by the manufacturer. RT-
PCR was used for the analysis of Survivin mRNA with
GAPDH as an internal control. Primers for Survivin were
as follow: forward primer 5'-GAC CAC CGC ATC TCT
ACA TTC-3', reverse primer 5'-GTT CTT GGC TCT TTC
TCT GTCC-3'. The GAPDH primers were forward 5'-ACC
ACA GTC CAT GCC ATC AC-3' and reverse 5'-TCC ACC
ACC CTG TTG CTG TA-3'. Reactions were performed in
accordance with the standard protocol. PCR was per-
formed by initial denaturation at 94°C for 5 min followed
by 35 cycles of 30 s at 94°C, 30 s at 58°C and 60 s at
72°C. The products were separated by electrophoresis in
2% agarose and visualized with ethidium bromide. Exper-
iments were performed in triplicate.
Western blot analysis
Cells were transfected with adenoviruses and incubated
for 48 h. After that they were harvested and the protein
extracts were separated via sodium dodecyl sulfate-poly-
acdene gel electrophoresis and transferred onto nitrocel-
lulose membranes. The membranes were then blocked
with rabbit anti-Survivin, Ad2 E1A, β-actin (Santa Cruz),
XIAP (Sigma) and caspase-3 (Beyotime, China) primary
polyclonal antibodies respectively at 4°C overnight. After
washing with PBS containing 0.05% Tween 20 the mem-Journal of Experimental & Clinical Cancer Research 2009, 28:81 http://www.jeccr.com/content/28/1/81
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branes were incubated with secondary antibody (goat
anti-rabbit, Santa Cruz) for 2 h. They were visualized by
chemiluminescence system according to manufacturer's
instruction.
In vitro cytopathic assay
Cells were grown subconfluently and infected with aden-
oviruses with indicated MOIs. 5 days later, the medium
was removed and the cells were washed with PBS twice,
exposed to Coomassie brilliant blue and then washed
with distilled water. The result was documented as photo-
graphs.
MTT cell viability assay
To quantify the cytopathic effect, MTT assay was per-
formed. Cells were seeded in 96-well plates for 24 h at 1 ×
104 per well. After 1 to 5 days of various viruses infection,
15 μl MTT (5 mg/ml in PBS) was added to each well for 4
h incubation at 37°C followed by the addition of 150 μl
DMSO. Absorbance at 570 nm was measured for cell via-
bility in each well.
Flow cytometry evaluation
Apoptosis of cells infected with adenoviruses at MOI of 5
was determined by flow cytometry (FCM) using Annexin
V: PE Apoptosis Detection Kit I (BD Biosciences, USA)
according to manufacturer's instruction. Briefly, Cells
were washed twice with cold PBS and resuspended in
binding buffer at a concentration of 1 × 105 cells/ml. Then
they were incubated with 5 μl of PE Annexin V and 5 μl of
7-AAD for 15 min at room temperature in the dark. At last,
400 μl of binding buffer was added and cells were ana-
lyzed by flow cytometry.
Animal studies
Five-week-old, female BALBC/C nude mice were obtained
from the Laboratory Animal Center of Chongqing Medi-
cal University. They were maintained in the specific path-
ogen free unit under isothermal conditions. All
experimental procedures were carried out in accordance
with the National Institute of Health Guide for the Care
and Use of Laboratory Animals.
5 × 106 SW480 cells suspended in 0.1 ml serum free
medium were implanted subcutaneously into the flank of
nude mice. When tumors size reached about 100 mm3,
mice were randomly divided into 5 groups with 6 mice in
each group. ZD55-Sur-EGFP, ZD55-EGFP, AD-Sur-EGFP
and AD-EGFP were injected through the tail vein with 5 ×
108 PFU adenoviruses suspended in 100 μl PBS or 100 μl
PBS alone for 3 days. Tumors were monitored by measur-
ing tumor volume with a caliper. The volume was calcu-
lated by the formula: V (mm3) = length × width2/2. After
60 days experiment, the tumors were harvested for west-
ern blot analysis.
Survivin protein expression in xenograft tumor
Snap-frozen tumor samples were homogenized mechani-
cally in a buffer (150 mM sodium chloride, 0.1 M Tris (pH
8), 1% Tween-20, 50 mM diethyldithiocarbamic acid, 1
mM EDTA pH 8) containing protease inhibitors, before
sonication and centrifugation at 4°C for 3 min. The fol-
lowing steps were the same as above mentioned in the
western blot analysis part.
Statistical analysis
All data were displayed as Mean ± S0D, analyzed via anal-
ysis of variance and Student t test, and processed by the
statistical software SPSS 13.0. Statistical significance was
assumed when p < 0.05.
Results
Adenovirus construction and identification
The recombinant adenoviral vector plasmid pZD55 had
been constructed and reserved in our laboratory. Recom-
binant oncolytic adenovirus ZD55-Sur-EGFP was con-
structed by homologous recombination between pZD55-
Sur-EGFP and the packaging plasmid pBHGE3. The sche-
matic picture shows the recombinant ZD55-Sur-EGFP
(Shown in Fig 1). The result was confirmed by restrictive
enzyme digestion assay and sequence assay. E1A expres-
sion was also examined by immunoblot with SW480 and
LoVo cells infected with various adenoviruses, shown in
Fig 2. Results showed cells transfected with oncolytic
viruses expressed E1A protein.
The schematic presentation of ZD55-Sur-EGFP Figure 1
The schematic presentation of ZD55-Sur-EGFP. The 
E1B-55KD gene was replaced by Survivin-shRNA sequence 
expression cassette and EGFP.Journal of Experimental & Clinical Cancer Research 2009, 28:81 http://www.jeccr.com/content/28/1/81
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Reporter gene assay in vitro
As shown in Fig 3a, the ZD55-Sur-EGFP demonstrated a
high specificity to cancer cells. After 48 h, stronger green
fluorescence was observed in SW480 and LoVo cells
infected with ZD55-Sur-EGFP than with AD-Sur-EGFP at
MOI of 5. On the contrary, ZD55-Sur-EGFP showed much
lower affinity to normal IEC cells compared with AD-Sur-
EGFP. After 72 h, the cancer cells infected with ZD55-Sur-
EGFP became lysed but there was little change in the mor-
phology of AD-Sur-EGFP infected cells.
Inhibition of Survivin gene expression
RT-PCR was performed 48 h after infection at MOI of 10.
Both ZD55-Sur-EGFP and AD-Sur-EGFP suppressed the
expression of Survivin mRNA in SW480 and LoVo cells
significantly, whereas ZD55-EGFP and Ad-EGFP showed
little inhibition on Survivin mRNA. The Survivin protein
expression analyzed by western blot was consistent with
results from RT-PCR. The gels were analyzed by Image-
Master Total Lab software. Results showed ZD55-Sur-
EGFP and AD-Sur-EGFP significantly down regulated the
expression of Survivin protein but ZD55-EGFP and AD-
EGFP had little effect on Survivin expression. Importantly,
infection of neither ZD55-Sur-EGFP nor AD-Sur-EGFP
affected the expression of another anti-apoptotic protein
XIAP. (Fig 4)
Inhibition on in vitro growth and viability
To detect the specific cytopathic effect of ZD55-Sur-EGFP
in tumor cells, SW480, LoVo, as well as IEC cells, were
infected with various adenoviruses at indicated MOIs. As
shown in Fig 5. Marked cytopathic effect was observed in
both tumor cell lines infected with ZD55-Sur-EGFP com-
pared with ZD55-EGFP, AD-Sur-EGFP and AD-EGFP
infected cells even at low MOIs. And ZD55-Sur-EGFP
caused limited cell death in normal cell line IEC.
MTT cell viability assay demonstrated that SW480 and
LoVo cells infected with ZD55-Sur-EGFP showed a signif-
icantly stronger CPE in a time-dependent manner. ZD55-
Sur-EGFP could kill colorectal cancer cells more power-
fully compared with other groups (Fig 6).
Apoptosis induced by adenoviruses
As shown in Fig 7, the transfection of oncolytic adenovi-
ruse with Survivin shRNA remarkably increased apoptotic
populations in SW480 and LoVo cells by FCM analysis.
The apoptotic rate in cancer cells transfected with ZD55-
Sur-EGFP (68.02% and 63.79%) was of great statistic sig-
nificance compared with ZD55-EGFP (10.46% and
13.38%), AD-Sur-EGFP (27.57% and 31.09%) and AD-
EGFP (6.14 and 6.74%) groups
To confirm the apoptosis was mediated by caspase activa-
tion, we next examined the caspase-3 activation by immu-
noblot analysis. In both SW480 and LoVo cells, the
cleaved fragments of caspase-3 increased along with the
decrease of procaspase-3 in ZD55-Sur-EGFP and AD-Sur-
EGFP infected groups, and the activation of caspase-3 was
more obvious in ZD55-Sur-EGFP group. Infections with
ZD-EGFP and AD-EGFP did not affect the status of cas-
pase-3 (Fig 8).
Effects of AD-Sur-EGFP on in vivo xenograft tumor model
To further investigate the antitumor effect of oncolytic
adenovirus mediated Survivin knock down on the in vivo
CRC tumor growth. SW480 cells suspended in serum free
medium were subcutaneously implanted into nude mice
and various adenoviruses were injected via tail vein. 60
days later the mice were sacrificed and tumors were
resected. The PBS treated group outgrowth other groups
(2536.44 mm3 in volume). The mean volume of ZD55-
Sur-EGFP group was 108.80 mm3, which was much
E1A expression in SW480 and LoVo cells infected with ZD55-Sur-EGFP, ZD55-EGFP, AD-Sur-EGFP and AD-EGFP by immu- noblot Figure 2
E1A expression in SW480 and LoVo cells infected with ZD55-Sur-EGFP, ZD55-EGFP, AD-Sur-EGFP and AD-
EGFP by immunoblot. AD-Sur-EGFP and AD-EGFP were E1A deleted viruses, the E1A protein was absent in this analysis.Journal of Experimental & Clinical Cancer Research 2009, 28:81 http://www.jeccr.com/content/28/1/81
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smaller than the ZD55-EGFP group (863.56 mm3), AD-
Sur-EGFP group (1224.97 mm3), AD-EGFP group
(2278.21 mm3) and PBS treated group (Fig 9a,b).
Western blot analysis of Survivin in xenograft tumors
To determine the effect of ZD55-Sur-EGFP on Survivin
expression in vivo, we analyzed the Survivin protein in by
western blot. As shown in Fig 9c, Survivin showed a
marked reduction in ZD55-Sur-EGFP and AD-Sur-EGFP
treated groups when compared with the PBS, AD-EGFP
and ZD55-EGFP group. Furthermore, it is clearly that
ZD55-Sur-EGFP suppressed Survivin expression more
potent than AD-Sur-EGFP, and ZD55-EGFP, AD-EGFP
and PBS had nearly no effect on Survivin expression.
Discussion
Colorectal carcinoma is the most frequent alimentary sys-
tem malignancy, which accounts for 40% of the estimated
new cancer cases of the digestive tract [12]. Although the
incidence of CRC in developed countries is slowly
decreasing, it is increasing rapidly in developing coun-
tries. Treatments such as surgical operation, adjuvant
chemotherapy and neo adjuvant chemotherapy have
achieved great progress [13], but the reported survival rate
of CRC within five years is not yet encouraging. The mor-
tality of CRC is mainly due to metastasis to distant organs,
especially to liver, which accounts for one-third of the
metastatic colorectal cancers [14-18]. It is urgent to estab-
lish a more effective therapeutics for CRC.
SW480 and LoVo cells as well as IEC cells were plated at 105 cells per 6 cm dishes and infected with ZD55-Sur-EGFP (A) or  AD-Sur-EGFP (B) for 48 h (a) or 72 h (b) Figure 3
SW480 and LoVo cells as well as IEC cells were plated at 105 cells per 6 cm dishes and infected with ZD55-Sur-
EGFP (A) or AD-Sur-EGFP (B) for 48 h (a) or 72 h (b). Then the cells were observed through a fluorescence micro-
scope. ZD55-Sur-EGFP showed much stronger affinity to SW480 cells than AD-Sur-EGFP, but it rarely replicated in normal 
cells IEC at 24 h post infection. After 72 h, the cells infected with ZD55-Sur-EGFP became lysed but there was little change in 
the morphology of AD-Sur-EGFP infected cells. (Original magnification ×200).Journal of Experimental & Clinical Cancer Research 2009, 28:81 http://www.jeccr.com/content/28/1/81
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Inhibition of Survivin mRNA and protein expression in SW480 and LoVo cells Figure 4
Inhibition of Survivin mRNA and protein expression in SW480 and LoVo cells. The cancer cells were treated with 
ZD55-Sur-EGFP, ZD55-EGFP, AD-Sur-EGFP and AD-EGFP respectively at MOI of 10. a: AD-EGFP group b: ZD55-EGFP group 
c: AD-Sur-EGFP group d: ZD55-Sur-EGFP group. (A) RT-PCR showed significant reduction of Survivin mRNA in ZD55-Sur-
EGFP and AD55-Sur-EGFP treated cells. (B) Survivin protein levels in above mentioned groups were consistent with mRNA 
expression by Westen blot, and XIAP protein expression was not affected. **P < 0.0001, *P < 0.05Journal of Experimental & Clinical Cancer Research 2009, 28:81 http://www.jeccr.com/content/28/1/81
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RNA interference (RNAi) is a posttranscriptional gene
silencing strategy first discovered in the nematode
Caenorhabditis elegans [19]. Because of its high specifity
and efficiency in down regulating gene expression, it has
now become an excellent tool for exploring gene function.
Many groups have worked on cancer gene silencing using
RNAi in cell lines derived from different tissues, which
lead to significant inhibition in cancer cell growth [20-
24]. Also there are some in vivo studies using RNA inter-
ference strategies which achieve similar results [7,25]. But
the transfection efficiencies of traditional RNAi strategies
are relatively low. In order to facilitate the application of
RNAi in cancer gene therapies, improved methods for effi-
cient introduction of small interfering RNA (siRNA) into
target cells are needed.
Oncolytic adenovirus as an anticancer agent is a potent
treatment in various malignancies [26]. The best known
oncolytic adenovirus named ONYX-015 is an E1B-55 kDa
deficiency virus, which has shown promising results in
head-and-neck cancer treatment combining with chemo-
therapy [27,28]. Another oncolytic adenovirus, H101,
similar to ONYX-015, was recently approved by the Chi-
nese government to be used in combination with radio-
therapy for head-and-neck cancers too [29]. Many works
have been done to increase the efficacy of oncolytic aden-
ovirus virotherapy. Oliver and his colleagues constructed
an oncolytic adenovirus expressing Herpes Simplex Virus-
thymidine kinase which showed significant anti-neoplas-
tic activity [30]. Another team from Taiwan used an E1B-
deleted adenovirus driven by the squamous cell carci-
noma cell antigen 2 promoter for uterine cervical cancer
therapy [26]. Sagawa and his colleagues reported a suc-
cessful inhibition of hepatocellular carcinoma by com-
bining conditionally replicable adenovirus driven by α-
fetoprotein enhancer/promoter (AFPep) with a replica-
tion-incompetent adenovirus carrying a p53 transgene
also driven by AFPep [31]. But there is no report so far
combining the oncolytic adenovirus with RNA interfer-
ence in colorectal malignancy treatment.
ZD55 is a new E1B 55 kDa deleted adenovirus vector
which replicates specifically in tumor cells and lyses them.
Researchers had successfully armed different therapeutic
genes with ZD55 and showed significant antitumor effects
[32]. To improve the efficiency and potency of Survivin
shRNA, we constructed ZD55-Sur-EGFP, an E1B 55 kDa
deleted adenovirus carrying a Survivin targeted shRNA
and a reporter gene.
In our study, we found the selectivity of ZD55-Sur-EGFP
was much more obvious than that of AD-Sur-EGFP in
colorectal cancer cell lines by reporter gene assay. We
demonstrated that shRNA expressed from ZD55-Sur-
EGFP significantly decreased Survivin expression of color-
ectal cancer cells as compared with AD-Sur-EGFP, but
ZD55-EGFP and AD-EGFP had nearly no effect on Sur-
vivin expression. Moreover, the cytopathic effect of ZD55-
Sur-EGFP on the tumor cell lines was more apparent than
that of ZD55-EGFP, AD-Sur-EGFP and AD-EGFP. These
results suggest the selectivity of ZD55 could amplify the
copies of shRNA in tumor cells and allow the viral infec-
tion to adjacent tumor cells, which further enhanced the
RNAi potency. Furthermore, the oncolytic effect and Sur-
vivin RNAi synergistically suppressed tumor cell growth,
leading to significant cell death.
The impact of oncolytic adenovirus mediated RNAi against  Survivin on SW480, LoVo and IEC cells Figure 5
The impact of oncolytic adenovirus mediated RNAi 
against Survivin on SW480, LoVo and IEC cells. Cells 
were seeded in a 24-well plate at 1 × 105 cells per well. Then 
they were infected with different adenoviruses at different 
MOIs. At last, cells were stained with Coomassie brilliant 
blue.Journal of Experimental & Clinical Cancer Research 2009, 28:81 http://www.jeccr.com/content/28/1/81
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Cells were transfected with ZD55-Sur-EGFP, ZD55-EGFP ADS-Sur-EGFP and AD-EGFP respectively at MOI of 5 Figure 6
Cells were transfected with ZD55-Sur-EGFP, ZD55-EGFP ADS-Sur-EGFP and AD-EGFP respectively at MOI 
of 5. On 1 to 5 days post transfection, cells were subjected to MTT assay. This diagram shows the result of cell viability in each 
group. *P < 0.0001 vs other groups.
Cell apoptosis was detected by flow cytometry Figure 7
Cell apoptosis was detected by flow cytometry. The apoptotic rates of SW480 and LoVo cells infected with ZD55-Sur-
EGFP were obviously higher (68.02% ± 6.88% and 63.79% ± 6.06%; P < 0.0001) than that of ZD55-EGFP (10.46% ± 2.31% and 
13.38% ± 3.05%), AD-Sur-EGFP (27.57% ± 2.49% and 31.09% ± 2.68%) and AD-EGFP groups (6.14% ± 0.72% and 6.74% ± 
0.47%).Journal of Experimental & Clinical Cancer Research 2009, 28:81 http://www.jeccr.com/content/28/1/81
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In our study, the data indicated ZD55-Sur-EGFP could
induce much stronger apoptosis in both colorectal cancer
cell lines than induced by ZD55-EGFP, AD-Sur-EGFP and
AD-EGFP by activating caspases. Interestingly, we found
infection of ZD55-EGFP had the potential to induce apop-
tosis, which was independent to Survivin regulation by
RT-PCR and immunoblot analysis. A possible explanation
is that some oncolytic virus structure proteins have an
effect on the induction of tumor cell apoptosis and virus
gene integration into the genome of cancer cells could
lead to increased susceptibility to apoptosis [33].
In our present study, another interesting finding was that
despite a remarkable induction of apoptosis as a conse-
quence of the inhibition of Survivin after both infections
of ZD55-Sur-EGFP and AD-Sur-EGFP, a significant
decrease of cell viability was observed only after infection
Effect of adenoviruses on caspase-3 activity in SW480 and  LoVo cells Figure 8
Effect of adenoviruses on caspase-3 activity in SW480 
and LoVo cells. Western blot analysis was performed 48 h 
post infection. The activation of caspase-3 (demonstrated as 
increased expression of cleaved fragments of caspase-3) was 
more obvious in ZD455-Sur-EGFP group (D) than in AD-
Sur-EGFP group (C), whereas AD-EGFP (A) and ZD55-EGFP 
(B) did not actvivate caspase-3.
Antitumor effects of oncolytic virus mediated Survivin RNAi in nude mice xenograft tumor model Figure 9
Antitumor effects of oncolytic virus mediated Survivin RNAi in nude mice xenograft tumor model. 4-week-old 
female BALBC/C nude mice were injected subcutaneously with SW480 cells and then with adenoviruses injected through the 
tail vein. After 60 days, the mice were sarcrificed and the tumors were harvested. A: AD-EGFP group B: ZD55-Sur-EGFP 
group C: ZD55-EGFP group D: AD-Sur-EGFP group E: PBS group (a) Representative tumor formations, 60 days after injection. 
(b) Tumor volume after 60 days of injection was quantitatively represented. Data were expressed as mean ± SD. *P < 0.01 vs 
other groups (c) Western blotting of proteins from xenograft tumors. The result was consistent with that on cell level.Journal of Experimental & Clinical Cancer Research 2009, 28:81 http://www.jeccr.com/content/28/1/81
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with ZD55-Sur-EGFP in MTT assay. This phenomenon
could be explained by the characteristics of both virus vec-
tors. AD-Sur-EGFP is a replication deficient adenovirus
which cannot replicate in tumor cells, initiating a limited
time of Survivin down regulation and cell apoptosis; on
the contrary, ZD55-Sur-EGFP can selectively replicate in
those cells, delivering Survivin shRNA and then lyses the
cells. This explanation is further confirmed by MTT assay:
during the first two days, the cell viabilities in AD-Sur-
EGFP group was lower than in ZD55-EGFP group, but
after 2 days, the cell viability in ZD55-EGFP group became
lower than AD-Sur-EGFP group because of the replication
of oncolytic virus.
Previous study has shown that adenovirus based RNAi
against Survivin led to significant inhibition of Survivin
expression and tumor growth in vivo [7]. Our xenograft
tumor model demonstrated that ZD55-Sur-EGFP has a
more potent antitumor activity than that of ZD55-EGFP,
AD-Sur-EGFP and AD-EGFP. Besides the direct anticancer
effect of the oncolytic virus itself, the much more efficient
Survivin shRNA delivering, gene silencing and induction
of apoptosis contribute greatly to the potent antitumor
activity.
Conclusion
In conclusion, the ZD55-Sur-EGFP has both the oncolytic
ability and the capacity to deliver Survivin shRNA. This
oncolytic adenovirus based Survivin RNA interference
could efficiently reduce the cell growth, tumorigenicity
and increase apoptosis of colorectal cancer cells, which
offers a prospect of improvement in treatment of CRC,
even a promising treatment for other human cancers.
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